MedTrace Logo

Dexamethasone and COVID-19 Inpatient Mortality

NCT04926571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14105

Last updated 2023-04-18

No results posted yet for this study

Summary

The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.

Conditions

  • Coronavirus

Interventions

DRUG

Dexamethasone Oral

New users of Dexamethasone

Sponsors & Collaborators

  • Aetion, Inc.

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-08-27
Completion
2021-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04926571 on ClinicalTrials.gov